EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

Platinum free interval and clinical benefit of the second-line chemotherapy in recurrent uterine and ovarian carcinosarcoma: a retrospective cohort analysis

Julie Berthet iD, Amel Kime iD, Bruno Borghese iD, Sixtine De Percin iD, Antoine Gaudet-Chardonnet iD, Jerome Alexandre iD, Guillaume Beinse iD

Journal of Gynecologic Oncology · 2025

DOI: 10.3802/jgo.2025.36.e64 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Gynecologic Oncology, 2025. Verfasst von Julie Berthet und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medical Oncology, Hopital Cochin, Sorbonne Université, Institut du Cancer Paris CARPEM, AP-HP, Paris, France. Hauptthemen laut MEDLINE: Carcinosarcoma, Ovarian Neoplasms, Uterine Neoplasms, Neoplasm Recurrence, Local. Die Arbeit nennt 34 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Institut du Cancer Paris CARPEM.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

OBJECTIVE: Uterine and ovarian carcinosarcomas (OCSs) are rare and aggressive neoplasms. We assessed whether progression free survival after initial treatment (PFS1) was associated with the clinical benefit of chemotherapy after progression, estimated as overall survival (OS) after progression/relapse. METHODS: All consecutive patients treated with chemotherapy for stage I-IV uterine/OCS in Cochin University Hospital between 2010 and 2022 were included in this retrospective cohort. Association between PFS1 and OS after progressive disease (PD) was determined by Cox regression. Optimal PFS1 threshold for OS after PD prediction was determined by a time-dependent receiver operating characteristic-curve analysis. RESULTS: Forty patients treated for endometrial (n=32) or OCS (n=8) were included. Median PFS1 and OS after PD were 16 months 95% confidence interval (95% CI=11-not available [NA]) and 6 months (95% CI=2-15). In patients who relapsed/progressed (n=20), OS after PD was anticipated by PFS1 (Pearson r=0.61; area under the curve=0.79; 95% CI=0.6-1). At the threshold of PFS1 ≤/>9 months (n=6/n=7), median OS post PD were 2 months (0.1-NA) and 15 months (6-NA), for patients treated with platinum/anthracycline based chemotherapy in second line. Patients receiving best supportive care alone (n=7) had a median OS post PD of 8 months (1.3-NA). CONCLUSION: Our results highlight that a subgroup of carcinosarcomas patients exhibits a durable benefit from chemotherapy in the relapse settings, and suggest the use of PFS1, as a proxy of platinum-sensitivity, to select patients who might derive higher clinical benefit of a 2nd line of chemotherapy.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

CarcinosarcomaOvarian NeoplasmsUterine NeoplasmsNeoplasm Recurrence, LocalAntineoplastic Combined Chemotherapy ProtocolsHumansFemaleRetrospective StudiesMiddle AgedAgedProgression-Free SurvivalAdultAged, 80 and over

Stichwörter der Autor:innen

CarboplatinCarcinosarcomaHomologous RecombinationPalliative CareRetrospective Study

Autor:innen und Institutionen

  • Department of Medical Oncology, Hopital Cochin, Sorbonne Université, Institut du Cancer Paris CARPEM, AP-HP, Paris, France.
  • Department of Pathology, Hopital Cochin, Institut du Cancer Paris CARPEM, AP-HP, Paris, France.
  • Centre de Recherche des Cordeliers, Equipe labélisée Ligue Contre le Cancer, CNRS SNC 5096, Sorbonne Université, Université de Paris, INSERM, Paris, France.
  • Department of Gynecological Surgery, Hopital Cochin, Université Paris Cité, Institut du Cancer Paris CARPEM, AP-HP, Paris, France.
  • Centre de Recherche des Cordeliers, Equipe labélisée Ligue Contre le Cancer, CNRS SNC 5096, Sorbonne Université, Université de Paris, INSERM, Paris, France. jerome.alexandre@aphp.fr.

ORCID-Profile: Julie Berthet, Amel Kime, Bruno Borghese, Sixtine De Percin, Antoine Gaudet-Chardonnet, Jerome Alexandre, Guillaume Beinse

Förderung

  • Institut du Cancer Paris CARPEM

Zitieren

APA

Berthet, J., Kime, A., Borghese, B., De Percin, S., Gaudet-Chardonnet, A., Alexandre, J., & Beinse, G. (2025). Platinum free interval and clinical benefit of the second-line chemotherapy in recurrent uterine and ovarian carcinosarcoma: a retrospective cohort analysis. Journal of Gynecologic Oncology. https://doi.org/10.3802/jgo.2025.36.e64

Vancouver

Berthet J, Kime A, Borghese B, De Percin S, Gaudet-Chardonnet A, Alexandre J, et al. Platinum free interval and clinical benefit of the second-line chemotherapy in recurrent uterine and ovarian carcinosarcoma: a retrospective cohort analysis. Journal of Gynecologic Oncology. 2025. doi:10.3802/jgo.2025.36.e64

BibTeX
@article{Berthet2025,
  author = {Berthet, Julie and Kime, Amel and Borghese, Bruno and De Percin, Sixtine and Gaudet-Chardonnet, Antoine and Alexandre, Jerome and Beinse, Guillaume},
  title = {Platinum free interval and clinical benefit of the second-line chemotherapy in recurrent uterine and ovarian carcinosarcoma: a retrospective cohort analysis},
  journal = {Journal of Gynecologic Oncology},
  year = {2025},
  doi = {10.3802/jgo.2025.36.e64}
}
Kostenlos starten →